Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma

被引：72

作者：

Lemieux, B ^{[1
]}

Tartas, S ^{[1
]}

Traulle, C ^{[1
]}

Espinouse, D ^{[1
]}

Thieblemont, C ^{[1
]}

Bouafia, F ^{[1
]}

Alhusein, Q ^{[1
]}

Antal, D ^{[1
]}

Salles, G ^{[1
]}

Coiffier, B ^{[1
]}

机构：

[1] Univ Lyon 1, Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Haematol, F-69495 Pierre Benite, France

来源：

BONE MARROW TRANSPLANTATION | 2004年 / 33卷 / 09期

关键词：

non-Hodgkin's lymphoma; rituximab; autologous transplantation;

D O I：

10.1038/sj.bmt.1704467

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Rituximab, an anti-CD20 monoclonal antibody, is increasingly used in the treatment of B-cell non-Hodgkin's lymphoma. Late-onset neutropenia in relation to rituximab has been recently described. In this report, we present six cases occurring after stem cell transplantation and discuss the potential impact of this complication.

引用

页码：921 / 923

页数：3

共 11 条

[1] Delayed-onset neutropenia associated with rituximab therapy [J].

Chaiwatanatorn, K ;

Lee, N ;

Grigg, A ;

Filshie, R ;

Firkin, F .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (06) :913-918

[2]

Coakley G, 2000, ARTHRITIS RHEUM, V43, P834, DOI 10.1002/1529-0131(200004)43:4<834::AID-ANR14>3.0.CO

[3]

2-H

[4] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[5] Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma [J].

Flinn, IW ;

O'Donnell, PV ;

Goodrich, A ;

Vogelsang, G ;

Abrams, R ;

Noga, S ;

Marcellus, D ;

Borowitz, M ;

Jones, R ;

Ambinder, RF .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2000, 6 (06) :628-632

[6] Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma:: Final analysis of the prospective LNH87-2 protocol -: A Groupe d'Etude des Lymphomes de l'Adulte Study [J].

Haioun, C ;

Lepage, E ;

Gisselbrecht, C ;

Salles, G ;

Coiffier, B ;

Brice, P ;

Bosly, A ;

Morel, P ;

Nouvel, C ;

Tilly, H ;

Lederlin, P ;

Sebban, C ;

Brière, J ;

Gaulard, P ;

Reyes, F .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :3025-3030

[7] Autoimmune thrombocytopenic purpura after autologous stem cell transplantation [J].

Hequet, O ;

Salles, G ;

Ketterer, N ;

Espinouse, D ;

Dumontet, C ;

Thieblemont, C ;

Arnaud, P ;

Bouafia, F ;

Coiffier, B .

BONE MARROW TRANSPLANTATION, 2003, 32 (01) :89-95

[8]

Liu JH, 2000, BLOOD, V95, P3219

[9] Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:: Half of patients respond to a four-dose treatment program [J].

McLaughlin, P ;

Grillo-López, AJ ;

Link, BK ;

Levy, R ;

Czuczman, MS ;

Williams, ME ;

Heyman, MR ;

Bence-Bruckler, I ;

White, CA ;

Cabanillas, F ;

Jain, V ;

Ho, AD ;

Lister, J ;

Wey, K ;

Shen, D ;

Dallaire, BK .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2825-2833

[10] Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases [J].

Papadaki, T ;

Stamatopoulos, K ;

Stavroyianni, N ;

Paterakis, G ;

Phisphis, M ;

Stefanoudaki-Sofianatou, K .

LEUKEMIA RESEARCH, 2002, 26 (06) :597-600

← 1 2 →